Seaport Therapeutics Inc. announced that it has priced an upsized initial public offering at $18.00 per share for 14,160,000 shares of common stock, with the price set at the top end of its previously stated range.
The company said it expects to receive gross proceeds of $254.9 million from the sale before accounting for underwriting discounts, commissions and offering-related expenses. In addition, Seaport granted the underwriters a 30-day option to acquire up to 2,124,000 additional shares at the IPO price, less underwriting discounts and commissions.
Shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker "SPTX." The offering is scheduled to close on May 4, 2026, subject to customary closing conditions. A registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on April 30, 2026.
The company named Goldman Sachs & Co. LLC, J.P. Morgan, Leerink Partners, Citigroup, and Stifel as joint book-running managers for the transaction.
Business focus and platform
Seaport Therapeutics is a clinical-stage developer of medicines targeting neuropsychiatric conditions, including depression, anxiety and other disorders within that therapeutic area. The firm uses its proprietary Glyph platform to create oral therapies designed to address limitations tied to clinically validated mechanisms - specifically aiming to improve issues such as high first-pass metabolism, low bioavailability and treatment-emergent side effects.
Investment product note included in the filing
In accompanying investor materials, an AI-driven stock idea service called ProPicks AI is referenced as evaluating SPTX alongside many other companies using more than 100 financial metrics. The material notes that the service applies AI to identify stocks based on fundamentals, momentum and valuation, and cites past winners including Super Micro Computer (+185%) and AppLovin (+157%). The material also invites readers to check whether SPTX appears in any current ProPicks AI strategies or to explore other opportunities in the same sector.
Summary
Seaport Therapeutics has priced an upsized IPO at $18 per share, with gross proceeds expected to be about $254.9 million and a 30-day underwriter option for additional shares. The company targets a Nasdaq listing on May 1, 2026 under the symbol SPTX and anticipates closing the offering on May 4, 2026, subject to standard conditions.
Key points
- Offering size and price: 14,160,000 shares at $18.00 per share, priced at the top of the target range; gross proceeds estimated at $254.9 million prior to fees.
- Underwriter option and fees: Underwriters have a 30-day option to buy up to 2,124,000 additional shares at the IPO price, less underwriting discounts and commissions; several major banks are joint book-runners.
- Clinical and platform focus: Seaport develops oral neuropsychiatric therapies using its Glyph platform to address metabolic and bioavailability limitations and side effects tied to validated mechanisms.
Risks and uncertainties
- The offering is subject to customary closing conditions, and the expected closing date of May 4, 2026 could change if those conditions are not met - impacting capital formation for the company and investor timing.
- Net proceeds are stated before underwriting discounts, commissions and offering expenses; actual funds available to the company will be reduced by those costs.
- The material references an AI-driven stock idea service and past performance of other stocks, but inclusion or performance of SPTX in such strategies is not guaranteed and represents a separate consideration from the company's fundamentals and clinical progress.
All information above reflects the details provided in the company's filing and statement around the IPO and related materials.